Immune Checkpoint Inhibitors (ICIs) targeting the Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) or Programmed cell death protein 1 (PD-1) pathways have demonstrated early success in treating various cancers. The gene discussed is CTLA4; the disease is cancer.